Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Unknown 1Terminated 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Prostatic Neoplasms 5Breast Neoplasms 5Uterine Cervical Neoplasms 2Cholangiocarcinoma 2Carcinoma, Intraductal, Noninfiltrating 2Sarcoma 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Lymphedema 1Lymphatic Metastasis 1Lung Neoplasms 1Glioblastoma 1Gallbladder Neoplasms 1Endometrial Neoplasms 1Encopresis 1Carcinoma, Non-Small-Cell Lung 1Breast Carcinoma In Situ 1Breast Cancer Female 1

Interventions

pembrolizumab 29Carboplatin 27Specimen Handling 21durvalumab 20Pemetrexed 18Cisplatin 17Paclitaxel 16atezolizumab 15Nivolumab 15Magnetic Resonance Spectroscopy 15osimertinib 11Radiosurgery 11Radiotherapy 10Immunoglobulin G 10Etoposide 10Docetaxel 10Disulfides 10Radiation 9Taxes 8Gemcitabine 8Biopsy 8Blood Specimen Collection 7Standard of Care 6Practice Guidelines as Topic 6Ipilimumab 6Surveys and Questionnaires 5Platinum 5Bronchoscopy 5Bevacizumab 5Ramucirumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Lung Neoplasms × Radiation Dose Hypofractionation × Clear all
NCT04310020 2026-05-13

Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients

National Cancer Institute (NCI)

Phase 2 Active not recruiting
47 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡